follow us:Google+ FacebookLinkedInTwitterRSS Feeds


Soligenix gets orphan drug designation for radiation treatment


Back to Top Comments Email Print

News You Can Use

Latest News


Princeton-based pharmaceutical company Soligenix announced today the Food and Drug Administration has granted it orphan drug designation for its acute radiation syndrome treatment, SGX94. The Office of Orphan Products Development granted the designation.

According to the announcement, in addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application, and certain tax credits.

Share This Story On:

Write to the Editorial Department at



Be the first to comment.

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
Back to Top